Medtech the Q4 star at J&J, but overall results seen as 'largely disappointing'
This article was originally published in Scrip
Executive Summary
Johnson & Johnson signalled the start of the earnings season on 22 January, with its fourth quarter and full-year 2012 results showing that its medical device and diagnostics division outperformed its pharmaceutical and consumer businesses.